Hennion & Walsh Asset Management, Inc. Revance Therapeutics, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $68,225 - $135,545	-4,761 Reduced 5.35%	84,259 $2.28 Million
Q2 2022 Jul 19, 2022	SELL	$11.52 - $20.4 $47,646 - $84,374	-4,136 Reduced 4.44%	89,020 $1.23 Million
Q1 2022 Apr 26, 2022	SELL	$12.36 - $20.31 $41,443 - $68,099	-3,353 Reduced 3.47%	93,156 $1.82 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $109,947 - $245,924	-8,824 Reduced 8.38%	96,509 $1.58 Million
Q3 2021 Nov 12, 2021	SELL	$25.78 - $33.21 $59,886 - $77,146	-2,323 Reduced 2.16%	105,333 $2.94 Million
Q2 2021 Aug 13, 2021	BUY	$26.8 - $31.84 $398,382 - $473,301	14,865 Added 16.02%	107,656 $3.19 Million
Q1 2021 May 17, 2021	BUY	$24.03 - $29.97 $2.23 Million - $2.78 Million	92,791 New	92,791 $2.59 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.